University of Vienna Research Shows Sutimlimab Promise with Cold Agglutinin Disease

Dec 18, 2018 | Cold Agglutinin Disease, University of Vienna

Chronic Blood Disorder

In a first-in-human clinical trial, the investigational drug sutimlimab appeared to be effective in treating cold agglutinin disease, a rare chronic blood disorder for which there are currently no approved treatments. Sutimlimab is a monoclonal antibody and was developed by Bioverative. The drug is an autoimmune disease characterized by the presence of high concentrations of circulating antibodies, usually IgM, directed against red blood cells, causing them to agglutinate and undergo lysis. It is a form of autoimmune hemolytic anemia, specifically one in which antibodies bind red blood cells only at low body temperatures, typically 28–31 °C.

Lead Research/Investigator

Bernd Jilma, MD, of the Medical University of Vienna.

0 Comments

Pin It on Pinterest